IQVIA

IQVIA offers several platforms that can be used across healthcare verticals, including healthcare operation management and life science technology. Its life sciences technology platform solutions assist companies with regard to clinical trial planning, compliance, obtaining real world evidence, and generating insights.

The company also offers solutions for medical adherence, healthcare operation optimization, brand strategy, and patient engagement. IQVIA is the subsidiary of public-listed healthcare technology company, IQVIA Holdings Inc. (NYSE:IQV).

In April 2021, IQVIA acquired 40% interest in Q2 Solutions for a consideration of USD 760 million. This transaction resulted in IQVIA gaining 100% ownership of Q2 Solutions.

In June 2024, the company launched One Home For Sites, a new platform that functions as a unified dashboard for the key systems and tasks required for clinical trials. One Home for Sites primarily acts as a central hub for all clinical applications used by a research site. It allows seamless integration of tools from different pharmaceutical sponsors and software vendors. Leaning on its ability as an aggregator, connector, and communicator, the platform aims to streamline the management of clinical trial procedures.

In October 2024, the company launched the IQVIA AI Assistant, a GenAI technology for life sciences customers. The AI Assistant is a conversational text interface that provides offers insights on brand and territory performance, competitive intelligence, and prescription drivers.

As of June 2024, IQVIA claimed to have processed over 120 billion healthcare records annually, had 61+ Petabytes of proprietary data, and supported over 500 studies, across 75+ countries.

Key customers and partnerships

In October 2023, IQVIA expanded its partnership with argenx, a biotechnology company, to advance autoimmune care. Through the partnership, the companies will collaborate to accelerate the expansion of clinical development and commercialization of new indications in autoimmune diseases. The partnership will involve IQVIA developing technology solutions tailored to argenx’s needs.

In April 2024, IQVIA expanded its partnership with Salesforce, a global cloud computing company, to accelerate the development of Salesforce’s Life Sciences Cloud, a customer engagement platform for the global life sciences sector. Using IQVIA's Orchestrated Customer Engagement (OCE) platform, which comprises data and analytics features, and Salesforce's Customer Relationship Management (CRM) solutions, the companies aimed to create a solution to provide an end-to-end engagement platform for life science companies. IQVIA agreed to license its engagement platform and associated software to Salesforce for the platform’s development. The companies projected that Salesforce Life Sciences Cloud would be ready for launch in 2025.

In September 2024, Signant Health joined IQVIA's One Home for Sites initiative to expand the availability of its eClinical solutions. The partnership allowed Signant's SmartSignals Unified Platform to be accessible through IQVIA's One Home for Sites, a collaborative platform designed for research staff to simplify clinical trial conduct using multiple eClinical technologies. The integration aimed to streamline access to various trial technologies from different providers through a single sign-on system, improving efficiency for clinical research sites.